StockData
Tandem Diabetes Care Inc logo

Tandem Diabetes Care Inc (TNDM) company profile

TNDMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3030% below fair value
$17.06−1.42 (-7.68%)

Close on Nov 17, 2026Market cap $1.19BP/E –Yield –

About Tandem Diabetes Care

Surgical & Medical Instruments & Apparatus, SIC 3841

Tandem Diabetes Care, Inc. develops, manufactures, and sells medical devices and digital tools for diabetes management. The company primarily produces durable insulin pump systems, notably the t:slim X2 and Tandem Mobi, which incorporate its Control-IQ+ automated insulin delivery technology. It also provides disposable supplies, such as insulin cartridges and infusion sets, along with software applications including the Tandem Source data management platform and the Sugarmate mobile app. These products serve individuals with insulin-dependent diabetes, including people with type 1 diabetes and individuals with type 2 diabetes requiring intensive insulin therapy.

The company serves nearly 500,000 customers in more than 25 countries globally. It markets its products in North America and international markets, utilizing direct sales teams and independent distributors across regions such as the United States, Canada, the United Kingdom, Austria, and Switzerland. Device assembly, testing, and packaging activities take place at company facilities located in San Diego, California.

Summary of the business section of Tandem Diabetes Care's latest annual report, written by StockData.

Company profile

Company

Legal name
Tandem Diabetes Care Inc
Founded
2008
Headquarters
San Diego, CA
Address
12400 High Bluff Drive 92130
Phone
(858) 366-6900
Employees
500,000, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
TNDM
Exchange
Nasdaq
IPO date
Nov 14, 2013
Shares outstanding
70M, Aug 3, 2026
Public float
$1.30B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-10 reverse, Oct 10, 2017
SEC CIK
1438133
CUSIP
875372203
ISIN
US8753722037
FIGI
BBG0019V9M65
Share class FIGI
BBG001TG5QC4
LEI
549300JEPFOD0K4D3I05
EIN
20-4327508

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Leigh VossellerEVP & CHIEF FINANCIAL OFFICER80,260
Rick CarpenterEVP & Chief Technology Officer33,378
Jean-Claude KyrillosEVP & Chief Operating Officer32,682
Shannon Marie HansenEVP & Chief Legal Officer35,064
Susan MorrisonEVP & Chief Admin. Officer54,806
Elizabeth Anne GasserEVP, Chief Strategy Officer35,901
Mark David NovaraEVP & CHIEF COMMERCIAL OFFICER37,732
John F. SheridanDirector168,077
Sandra BeaverDirector6,747
Christopher J. TwomeyDirector37,114
Kathleen McGroddy-GoetzDirector26,612
Myoungil ChaDirector22,458
Joao Paulo Falcao MalagueiraDirector22,458
Rajwant SodhiDirector24,280
Rebecca B. RobertsonDirector22,542
Peyton R. HowellDirector29,836
Kim D. BlickenstaffDirector183,038

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.86M$2.92M$1.97M$23$99
FY2024$8.53M$6.79M$1.95M$60$105
FY2023$4.65M$1.51M$1.50M$50$106
FY2022$6.38M-$8.34M$1.75M$75$100
FY2021$5.74M$16.41M$1.62M$253$125
FY2020$3.79M$11.40M$1.96M$161$130

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
John Sheridan
President and Chief Executive Officer
$790.58K$5.37M$674.09K$26.03K$6.86M-20%
Leigh Vosseller
Executive Vice President, Chief Financial Officer and Treasurer
$486.22K$1.42M$269.47K$8.35K$2.18M-12%
Elizabeth Gasser
Executive Vice President, Chief Strategy and Product Officer
$463.71K$1.04M$240.16K$8.35K$1.75M-13%
Shannon Hansen
Executive Vice President, Chief Legal, Privacy and Compliance Officer and Secretary
$463.71K$1.04M$237.60K$10.86K$1.75M–
Mark Novara
Executive Vice President, Chief Commercial Officer
$486.22K$1.42M$269.47K$31.06K$2.20M+175%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 14, 2013
Securities offered
7,143,000
Exchange
Nasdaq
First trading day
Nov 14, 2013
First-day close
$19.26
Lock-up ends (est.)
May 13, 2014

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“We serve nearly 500,000 people living with diabetes in more than 25 countries worldwide.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?